rewirebio.iobenchmarks
Source

LLMs for Bayesian Optimization in Scientific Domains: Are We There Yet?

Findings of the Association for Computational Linguistics: EMNLP 2025, pages 15482-15510 · Peer-reviewed

DOI: 10.48550/arXiv.2509.21403Original source

What this source contributed

Records in this release that cite this source. A record can cite several sources.

Results

Values as the source printed them. Compare results only under compatible protocols, datasets and metrics.

Model or configurationMetricValueDatasetEvaluation
BDA, llama-3-1-8b backbone (Gupta et al. 2025)True positives (cumulative hits after round 5; mean of 5 runs)32.4 countCarnevale et al. 2022 screen, T-cell resistance to tumour-microenvironment inhibitory signalsBDA (Llama-3.1-8B backbone) on Carnevale (Gupta et al. 2025)
BDA, llama-3-1-8b backbone (Gupta et al. 2025)True positives (cumulative hits after round 5; mean of 5 runs)44 countSchmidt et al. 2022 screen, interferon-gamma production in primary human T cellsBDA (Llama-3.1-8B backbone) on IFNG (Gupta et al. 2025)
BDA, llama-3-1-8b backbone (Gupta et al. 2025)True positives (cumulative hits after round 5; mean of 5 runs)39.4 countSchmidt et al. 2022 screen, interleukin-2 production in primary human T cellsBDA (Llama-3.1-8B backbone) on IL2 (Gupta et al. 2025)
BDA, llama-3-1-8b backbone (Gupta et al. 2025)True positives (cumulative hits after round 5; mean of 5 runs)23.2 countSanchez et al. 2021 screen, endogenous tau protein level in neuronsBDA (Llama-3.1-8B backbone) on Sanchez (Gupta et al. 2025)
BDA, llama-3-1-8b backbone (Gupta et al. 2025)True positives (cumulative hits after round 5; mean of 5 runs)43.6 countSanchez et al. 2021 screen, decreased endogenous tau protein level in neuronsBDA (Llama-3.1-8B backbone) on Sanchez Down (Gupta et al. 2025)
BDA, qwen-2-7b backbone (Gupta et al. 2025)True positives (cumulative hits after round 5; mean of 5 runs)27.2 countCarnevale et al. 2022 screen, T-cell resistance to tumour-microenvironment inhibitory signalsBDA (Qwen-2-7B backbone) on Carnevale (Gupta et al. 2025)
BDA, qwen-2-7b backbone (Gupta et al. 2025)True positives (cumulative hits after round 5; mean of 5 runs)26.2 countSchmidt et al. 2022 screen, interferon-gamma production in primary human T cellsBDA (Qwen-2-7B backbone) on IFNG (Gupta et al. 2025)
BDA, qwen-2-7b backbone (Gupta et al. 2025)True positives (cumulative hits after round 5; mean of 5 runs)33.2 countSchmidt et al. 2022 screen, interleukin-2 production in primary human T cellsBDA (Qwen-2-7B backbone) on IL2 (Gupta et al. 2025)
BDA, qwen-2-7b backbone (Gupta et al. 2025)True positives (cumulative hits after round 5; mean of 5 runs)26.4 countSanchez et al. 2021 screen, endogenous tau protein level in neuronsBDA (Qwen-2-7B backbone) on Sanchez (Gupta et al. 2025)
BDA, qwen-2-7b backbone (Gupta et al. 2025)True positives (cumulative hits after round 5; mean of 5 runs)26 countSanchez et al. 2021 screen, decreased endogenous tau protein level in neuronsBDA (Qwen-2-7B backbone) on Sanchez Down (Gupta et al. 2025)
BDA (Replicated), claude-3-5-sonnet backbone (Gupta et al. 2025)True positives (cumulative hits after round 5; mean of 5 runs)43.8 countCarnevale et al. 2022 screen, T-cell resistance to tumour-microenvironment inhibitory signalsBDA (Replicated) (Claude 3.5 Sonnet backbone) on Carnevale (Gupta et al. 2025)
BDA (Replicated), claude-3-5-sonnet backbone (Gupta et al. 2025)True positives (cumulative hits after round 5; mean of 5 runs)78.8 countSchmidt et al. 2022 screen, interferon-gamma production in primary human T cellsBDA (Replicated) (Claude 3.5 Sonnet backbone) on IFNG (Gupta et al. 2025)
BDA (Replicated), claude-3-5-sonnet backbone (Gupta et al. 2025)True positives (cumulative hits after round 5; mean of 5 runs)59.4 countSchmidt et al. 2022 screen, interleukin-2 production in primary human T cellsBDA (Replicated) (Claude 3.5 Sonnet backbone) on IL2 (Gupta et al. 2025)
BDA (Replicated), claude-3-5-sonnet backbone (Gupta et al. 2025)True positives (cumulative hits after round 5; mean of 5 runs)31.6 countSanchez et al. 2021 screen, endogenous tau protein level in neuronsBDA (Replicated) (Claude 3.5 Sonnet backbone) on Sanchez (Gupta et al. 2025)
BDA (Replicated), claude-3-5-sonnet backbone (Gupta et al. 2025)True positives (cumulative hits after round 5; mean of 5 runs)51.8 countSanchez et al. 2021 screen, decreased endogenous tau protein level in neuronsBDA (Replicated) (Claude 3.5 Sonnet backbone) on Sanchez Down (Gupta et al. 2025)
BDA (Reported Numbers), claude-3-5-sonnet backbone (Gupta et al. 2025)True positives (cumulative hits after round 5; mean of 5 runs)39.6 countCarnevale et al. 2022 screen, T-cell resistance to tumour-microenvironment inhibitory signalsBDA (Reported Numbers) (Claude 3.5 Sonnet backbone) on Carnevale (Gupta et al. 2025)
BDA (Reported Numbers), claude-3-5-sonnet backbone (Gupta et al. 2025)True positives (cumulative hits after round 5; mean of 5 runs)87.4 countSchmidt et al. 2022 screen, interferon-gamma production in primary human T cellsBDA (Reported Numbers) (Claude 3.5 Sonnet backbone) on IFNG (Gupta et al. 2025)
BDA (Reported Numbers), claude-3-5-sonnet backbone (Gupta et al. 2025)True positives (cumulative hits after round 5; mean of 5 runs)68.01 countSchmidt et al. 2022 screen, interleukin-2 production in primary human T cellsBDA (Reported Numbers) (Claude 3.5 Sonnet backbone) on IL2 (Gupta et al. 2025)
BDA (Reported Numbers), claude-3-5-sonnet backbone (Gupta et al. 2025)True positives (cumulative hits after round 5; mean of 5 runs)60.72 countSanchez et al. 2021 screen, endogenous tau protein level in neuronsBDA (Reported Numbers) (Claude 3.5 Sonnet backbone) on Sanchez (Gupta et al. 2025)
BDA (Reported Numbers), claude-3-5-sonnet backbone (Gupta et al. 2025)True positives (cumulative hits after round 5; mean of 5 runs)N/A countSanchez et al. 2021 screen, decreased endogenous tau protein level in neuronsBDA (Reported Numbers) (Claude 3.5 Sonnet backbone) on Sanchez Down (Gupta et al. 2025)
BDA-Rand, claude-3-5-sonnet backbone (Gupta et al. 2025)True positives (cumulative hits after round 5; mean of 5 runs)42 countCarnevale et al. 2022 screen, T-cell resistance to tumour-microenvironment inhibitory signalsBDA-Rand (Claude 3.5 Sonnet backbone) on Carnevale (Gupta et al. 2025)
BDA-Rand, claude-3-5-sonnet backbone (Gupta et al. 2025)True positives (cumulative hits after round 5; mean of 5 runs)79.4 countSchmidt et al. 2022 screen, interferon-gamma production in primary human T cellsBDA-Rand (Claude 3.5 Sonnet backbone) on IFNG (Gupta et al. 2025)
BDA-Rand, claude-3-5-sonnet backbone (Gupta et al. 2025)True positives (cumulative hits after round 5; mean of 5 runs)57.6 countSchmidt et al. 2022 screen, interleukin-2 production in primary human T cellsBDA-Rand (Claude 3.5 Sonnet backbone) on IL2 (Gupta et al. 2025)
BDA-Rand, claude-3-5-sonnet backbone (Gupta et al. 2025)True positives (cumulative hits after round 5; mean of 5 runs)33.8 countSanchez et al. 2021 screen, endogenous tau protein level in neuronsBDA-Rand (Claude 3.5 Sonnet backbone) on Sanchez (Gupta et al. 2025)
BDA-Rand, claude-3-5-sonnet backbone (Gupta et al. 2025)True positives (cumulative hits after round 5; mean of 5 runs)57.6 countSanchez et al. 2021 screen, decreased endogenous tau protein level in neuronsBDA-Rand (Claude 3.5 Sonnet backbone) on Sanchez Down (Gupta et al. 2025)
BDA-Rand, llama-3-1-8b backbone (Gupta et al. 2025)True positives (cumulative hits after round 5; mean of 5 runs)31.6 countCarnevale et al. 2022 screen, T-cell resistance to tumour-microenvironment inhibitory signalsBDA-Rand (Llama-3.1-8B backbone) on Carnevale (Gupta et al. 2025)
BDA-Rand, llama-3-1-8b backbone (Gupta et al. 2025)True positives (cumulative hits after round 5; mean of 5 runs)51 countSchmidt et al. 2022 screen, interferon-gamma production in primary human T cellsBDA-Rand (Llama-3.1-8B backbone) on IFNG (Gupta et al. 2025)
BDA-Rand, llama-3-1-8b backbone (Gupta et al. 2025)True positives (cumulative hits after round 5; mean of 5 runs)37 countSchmidt et al. 2022 screen, interleukin-2 production in primary human T cellsBDA-Rand (Llama-3.1-8B backbone) on IL2 (Gupta et al. 2025)
BDA-Rand, llama-3-1-8b backbone (Gupta et al. 2025)True positives (cumulative hits after round 5; mean of 5 runs)30.8 countSanchez et al. 2021 screen, endogenous tau protein level in neuronsBDA-Rand (Llama-3.1-8B backbone) on Sanchez (Gupta et al. 2025)
BDA-Rand, llama-3-1-8b backbone (Gupta et al. 2025)True positives (cumulative hits after round 5; mean of 5 runs)45 countSanchez et al. 2021 screen, decreased endogenous tau protein level in neuronsBDA-Rand (Llama-3.1-8B backbone) on Sanchez Down (Gupta et al. 2025)
BDA-Rand, qwen-2-7b backbone (Gupta et al. 2025)True positives (cumulative hits after round 5; mean of 5 runs)29 countCarnevale et al. 2022 screen, T-cell resistance to tumour-microenvironment inhibitory signalsBDA-Rand (Qwen-2-7B backbone) on Carnevale (Gupta et al. 2025)
BDA-Rand, qwen-2-7b backbone (Gupta et al. 2025)True positives (cumulative hits after round 5; mean of 5 runs)32.4 countSchmidt et al. 2022 screen, interferon-gamma production in primary human T cellsBDA-Rand (Qwen-2-7B backbone) on IFNG (Gupta et al. 2025)
BDA-Rand, qwen-2-7b backbone (Gupta et al. 2025)True positives (cumulative hits after round 5; mean of 5 runs)29 countSchmidt et al. 2022 screen, interleukin-2 production in primary human T cellsBDA-Rand (Qwen-2-7B backbone) on IL2 (Gupta et al. 2025)
BDA-Rand, qwen-2-7b backbone (Gupta et al. 2025)True positives (cumulative hits after round 5; mean of 5 runs)24.2 countSanchez et al. 2021 screen, endogenous tau protein level in neuronsBDA-Rand (Qwen-2-7B backbone) on Sanchez (Gupta et al. 2025)
BDA-Rand, qwen-2-7b backbone (Gupta et al. 2025)True positives (cumulative hits after round 5; mean of 5 runs)35.4 countSanchez et al. 2021 screen, decreased endogenous tau protein level in neuronsBDA-Rand (Qwen-2-7B backbone) on Sanchez Down (Gupta et al. 2025)
GP over llama-3-1-8b embeddings (Gupta et al. 2025)True positives (cumulative hits after round 5; mean of 5 runs)22.2 countCarnevale et al. 2022 screen, T-cell resistance to tumour-microenvironment inhibitory signalsGP (Llama-3.1-8B backbone) on Carnevale (Gupta et al. 2025)
GP over llama-3-1-8b embeddings (Gupta et al. 2025)True positives (cumulative hits after round 5; mean of 5 runs)23 countSchmidt et al. 2022 screen, interferon-gamma production in primary human T cellsGP (Llama-3.1-8B backbone) on IFNG (Gupta et al. 2025)
GP over llama-3-1-8b embeddings (Gupta et al. 2025)True positives (cumulative hits after round 5; mean of 5 runs)147.8 countSchmidt et al. 2022 screen, interleukin-2 production in primary human T cellsGP (Llama-3.1-8B backbone) on IL2 (Gupta et al. 2025)
GP over llama-3-1-8b embeddings (Gupta et al. 2025)True positives (cumulative hits after round 5; mean of 5 runs)27.6 countSanchez et al. 2021 screen, endogenous tau protein level in neuronsGP (Llama-3.1-8B backbone) on Sanchez (Gupta et al. 2025)
GP over llama-3-1-8b embeddings (Gupta et al. 2025)True positives (cumulative hits after round 5; mean of 5 runs)30 countSanchez et al. 2021 screen, decreased endogenous tau protein level in neuronsGP (Llama-3.1-8B backbone) on Sanchez Down (Gupta et al. 2025)
GP over qwen-2-7b embeddings (Gupta et al. 2025)True positives (cumulative hits after round 5; mean of 5 runs)22.2 countCarnevale et al. 2022 screen, T-cell resistance to tumour-microenvironment inhibitory signalsGP (Qwen-2-7B backbone) on Carnevale (Gupta et al. 2025)
GP over qwen-2-7b embeddings (Gupta et al. 2025)True positives (cumulative hits after round 5; mean of 5 runs)23 countSchmidt et al. 2022 screen, interferon-gamma production in primary human T cellsGP (Qwen-2-7B backbone) on IFNG (Gupta et al. 2025)
GP over qwen-2-7b embeddings (Gupta et al. 2025)True positives (cumulative hits after round 5; mean of 5 runs)147.8 countSchmidt et al. 2022 screen, interleukin-2 production in primary human T cellsGP (Qwen-2-7B backbone) on IL2 (Gupta et al. 2025)
GP over qwen-2-7b embeddings (Gupta et al. 2025)True positives (cumulative hits after round 5; mean of 5 runs)27.6 countSanchez et al. 2021 screen, endogenous tau protein level in neuronsGP (Qwen-2-7B backbone) on Sanchez (Gupta et al. 2025)
GP over qwen-2-7b embeddings (Gupta et al. 2025)True positives (cumulative hits after round 5; mean of 5 runs)30 countSanchez et al. 2021 screen, decreased endogenous tau protein level in neuronsGP (Qwen-2-7B backbone) on Sanchez Down (Gupta et al. 2025)
Linear UCB over llama-3-1-8b embeddings (Gupta et al. 2025)True positives (cumulative hits after round 5; mean of 5 runs)38 countCarnevale et al. 2022 screen, T-cell resistance to tumour-microenvironment inhibitory signalsLinear UCB (Llama-3.1-8B backbone) on Carnevale (Gupta et al. 2025)
Linear UCB over llama-3-1-8b embeddings (Gupta et al. 2025)True positives (cumulative hits after round 5; mean of 5 runs)72 countSchmidt et al. 2022 screen, interferon-gamma production in primary human T cellsLinear UCB (Llama-3.1-8B backbone) on IFNG (Gupta et al. 2025)
Linear UCB over llama-3-1-8b embeddings (Gupta et al. 2025)True positives (cumulative hits after round 5; mean of 5 runs)35 countSchmidt et al. 2022 screen, interleukin-2 production in primary human T cellsLinear UCB (Llama-3.1-8B backbone) on IL2 (Gupta et al. 2025)
Linear UCB over llama-3-1-8b embeddings (Gupta et al. 2025)True positives (cumulative hits after round 5; mean of 5 runs)39 countSanchez et al. 2021 screen, endogenous tau protein level in neuronsLinear UCB (Llama-3.1-8B backbone) on Sanchez (Gupta et al. 2025)
Linear UCB over llama-3-1-8b embeddings (Gupta et al. 2025)True positives (cumulative hits after round 5; mean of 5 runs)42 countSanchez et al. 2021 screen, decreased endogenous tau protein level in neuronsLinear UCB (Llama-3.1-8B backbone) on Sanchez Down (Gupta et al. 2025)

Claims

Statements this source supports, each with where in the source it was checked.

  • Baseline: Select therapeutic targets for validation: Baseline Random and pathway-based selection (tgtval-20261009-source-roohani2025: Appendix (human pathway baseline) and Table 6 (pathways), Table 2 (Random); tgtval-20261009-source-gupta2025: baselines description and Table 3 (Random))
  • control_result: tgtval-20261009-protocol-gupta2025-cumulative-hits-round5: Control result The source states that replacing true outcomes with randomly permuted labels has no impact on performance, and concludes that the language models tested fail to perform in-context experimental design. It performs two levels of randomisation: random measurement values, and random hit or not-hit feedback. In Table 1 the permuted variant scores at least as high as the agent on three of the five screens with each of the three backbones: Llama-3.1-8B, Qwen-2-7B, and Claude 3.5 Sonnet compared with the replicated row. (Abstract; section 5; Table 1 and its caption)
  • cross_source_consistency: tgtval-20261009-protocol-gupta2025-cumulative-hits-round5: Cross source consistency The 'BDA (Reported Numbers)' row divided by the printed ground-truth hit counts reproduces the all-gene hit ratios of Roohani et al. 2025 Table 1 for Claude 3.5 Sonnet to the printed rounding: IL2 68.01/654 = 0.104 against 0.104, IFNG 87.4/920 = 0.095 against 0.095, Carnevale 39.6/943 = 0.042 against 0.042 and Sanchez 60.72/924 = 0.0657 against 0.066. This indicates that both sources score against the same screens and the same hit sets, and that the row converts the original results rather than reporting a new run. The conversion used values more precise than Roohani Table 1 prints: 0.066 x 924 = 60.98, while the row prints 60.72. Checked during extraction; no value was altered. (Gupta et al. 2025 Tables 1 and 2 against Roohani et al. 2025 Table 1)
  • denominator: tgtval-20261009-protocol-gupta2025-cumulative-hits-round5: Denominator Printed ground-truth hit counts |C_gt| per screen: IL2 654, IFNG 920, Carnevale 943, Sanchez 924, Sanchez Down 924. The same five values are printed in Tables 1, 2 and 3. (Tables 1, 2 and 3, row 'Ground truth (| Cgt |)')
  • Evidence summary: therapeutic target validation: Summary Three sources compare target-nomination methods against measured CRISPR screen outcomes, and all three are retrospective replays of published screens: a method picks genes and the screen's existing measurement is looked up. Non-hits are genes the screen assayed that did not meet its criterion; genes a screen never assayed are outside the candidate pool or, in AssayBench's headline metric, removed before scoring, so these results say nothing about an untested target. Roohani et al. 2025 (ICLR) were run by the developers of the agent they test, two of whom are authors of two of the screens, and they state that patent applications have been filed on the findings. They report the fraction of each screen's hits found after five rounds of 128 genes. With Claude 3.5 Sonnet the agent reached 0.095 on the interferon-gamma screen, 0.104 on interleukin-2, 0.130 on CAR-T proliferation, 0.326 on lysosomal choline recycling, 0.042 on T-cell inhibition resistance and 0.066 on tau level, against random selection at 0.037, 0.031, 0.033, 0.160, 0.036 and 0.034. Conventional baselines were close on some screens: Coreset reached 0.102 on interleukin-2 and 0.047 on T-cell inhibition resistance, above the agent's 0.042 there. Gupta et al. 2025 (Findings of EMNLP), independent of the agent's authors, replayed five of the same screens and report cumulative hits. Their re-run of the Claude 3.5 Sonnet agent found fewer hits than the original numbers on three of four shared screens, for example 31.6 against 60.72 on tau level. Giving the agent randomly permuted feedback changed little: the permuted variant scored at least as high on three of five screens with each of the three backbones tested, for example 51 against 44 on interferon-gamma with Llama-3.1-8B, and the authors conclude that the models they tested do not perform in-context experimental design. Gaussian process optimisation over the same embeddings reached 147.8 hits on interleukin-2 against the agent's 39.4 with Llama-3.1-8B, from 654 ground-truth hits; the source prints identical Gaussian process values under both backbones. De Brouwer et al. 2026, a preprint that is not peer reviewed, asked 16 systems to rank 100 genes for each of 571 benchmark entries, each a described screen. On the 334 test entries the best system was an evolved ensemble of language models at 0.1631 adjusted NDCG@100 and the best single model, Gemini 3 Pro, 0.1570, against 0.1334 for a baseline ranking genes by how often they are hits in training screens of the same phenotype and 0.2918 for a retrieval upper bound that uses the answer. Most systems scored lower on the 19 entries published after the models' training cutoff, the ensemble falling to 0.1088, which that source reads as partly prior exposure to the literature. None of these sources tests a prospective validation batch, a target's usefulness, dependency, tractability or therapeutic window, or whether modulating a target benefits patients. (tgtval-20261009-source-roohani2025: Table 1, sections 2 and 4.1, conflicts of interest; tgtval-20261009-source-gupta2025: Tables 1 and 2, abstract, section 5; tgtval-20261009-source-debrouwer2026: Tables 2 and 3, sections 2 to 5)
  • Llama-3.1-8B: description: Description Language model in Meta's Llama 3 herd, which natively supports multilinguality, coding, reasoning and tool use. (qa-descriptions-20261011-b-source-llama3: abstract ('a herd of language models that natively support multilinguality, coding, reasoning, and tool usage'))
  • Qwen-2-7B: description: Description Language model in the Qwen2 series, a suite of foundational and instruction-tuned language models from 0.5 to 72 billion parameters. (qa-descriptions-20261011-b-source-qwen2: abstract)
  • Relevance of tgtval-20261009-protocol-gupta2025-cumulative-hits-round5 to "Which targets should I test to change a defined disease-relevant phenotype?": Assessed by Independent replication of 1-gene perturbation design: cumulative hits after 5 rounds of 128 genes (tgtval-20261009-source-gupta2025: Sections 4.1, 5 and 6; Tables 1 and 2; appendix B.1.1)

Models, benchmarks and other records

Models (2)

Methods (4)

Configurations (11)

Protocols (1)

Datasets (5)

Evaluations (55)

Use cases (1)

Evidence

Source checking verifies the cited claim or transcription. It does not establish independent reproduction.

Evidence table

Inspect claims, sources and review details

Trace each statement to its source and review. A context-only reference supports the record generally; it does not verify an individual field. Source checking does not reproduce an experiment.

One row per statement and cited source. Multiple citations are not independent evaluations. Shared locators are labelled explicitly.

22 evidence rows matching the loaded filters

Claims, original sources and review scope · Release 2026-11-02-a7f03c9e55a5
Property and statementOriginal source and locationReview and provenance
Access and reuse
CC-BY-4.0 permits redistribution of the article bytes.
Source metadata
LLMs for Bayesian Optimization in Scientific Domains: Are We There Yet?

Original source ↗

No field-specific location recorded

Version: Findings of the Association for Computational Linguistics: EMNLP 2025, pages 15482-15510
Retrieved: 2026-10-09T20:55:36Z

catalogued

No individual claim review recorded

Audit details

Field: attributes.access_and_reuse

Source artifact SHA-256: 7dda0b590f2736b7d30e48b97167a0868a2b4bde253589d8aff7929d01506ff9

Hash scope: pdftotext -layout text layer, parsed by extract/extract_target_validation.py

Inspected artifact

Archive note
Not archived in the batch although the licence permits it: the PDF is 475,883 bytes and the repository keeps releases small. The artifact_sha256 pins the bytes that were read.
Source metadata
LLMs for Bayesian Optimization in Scientific Domains: Are We There Yet?

Original source ↗

No field-specific location recorded

Version: Findings of the Association for Computational Linguistics: EMNLP 2025, pages 15482-15510
Retrieved: 2026-10-09T20:55:36Z

catalogued

No individual claim review recorded

Audit details

Field: attributes.archive_note

Source artifact SHA-256: 7dda0b590f2736b7d30e48b97167a0868a2b4bde253589d8aff7929d01506ff9

Hash scope: pdftotext -layout text layer, parsed by extract/extract_target_validation.py

Inspected artifact

Artifact SHA-256
7dda0b590f2736b7d30e48b97167a0868a2b4bde253589d8aff7929d01506ff9
Source metadata
LLMs for Bayesian Optimization in Scientific Domains: Are We There Yet?

Original source ↗

No field-specific location recorded

Version: Findings of the Association for Computational Linguistics: EMNLP 2025, pages 15482-15510
Retrieved: 2026-10-09T20:55:36Z

catalogued

No individual claim review recorded

Audit details

Field: attributes.artifact_sha256

Source artifact SHA-256: 7dda0b590f2736b7d30e48b97167a0868a2b4bde253589d8aff7929d01506ff9

Hash scope: pdftotext -layout text layer, parsed by extract/extract_target_validation.py

Inspected artifact

Artifact url
https://aclanthology.org/2025.findings-emnlp.838.pdf
Source metadata
LLMs for Bayesian Optimization in Scientific Domains: Are We There Yet?

Original source ↗

No field-specific location recorded

Version: Findings of the Association for Computational Linguistics: EMNLP 2025, pages 15482-15510
Retrieved: 2026-10-09T20:55:36Z

catalogued

No individual claim review recorded

Audit details

Field: attributes.artifact_url

Source artifact SHA-256: 7dda0b590f2736b7d30e48b97167a0868a2b4bde253589d8aff7929d01506ff9

Hash scope: pdftotext -layout text layer, parsed by extract/extract_target_validation.py

Inspected artifact

Doi
10.48550/arXiv.2509.21403
Source metadata
LLMs for Bayesian Optimization in Scientific Domains: Are We There Yet?

Original source ↗

No field-specific location recorded

Version: Findings of the Association for Computational Linguistics: EMNLP 2025, pages 15482-15510
Retrieved: 2026-10-09T20:55:36Z

catalogued

No individual claim review recorded

Audit details

Field: attributes.doi

Source artifact SHA-256: 7dda0b590f2736b7d30e48b97167a0868a2b4bde253589d8aff7929d01506ff9

Hash scope: pdftotext -layout text layer, parsed by extract/extract_target_validation.py

Inspected artifact

Extraction method
pdftotext -layout text layer, parsed by extract/extract_target_validation.py
Source metadata
LLMs for Bayesian Optimization in Scientific Domains: Are We There Yet?

Original source ↗

No field-specific location recorded

Version: Findings of the Association for Computational Linguistics: EMNLP 2025, pages 15482-15510
Retrieved: 2026-10-09T20:55:36Z

catalogued

No individual claim review recorded

Audit details

Field: attributes.extraction_method

Source artifact SHA-256: 7dda0b590f2736b7d30e48b97167a0868a2b4bde253589d8aff7929d01506ff9

Hash scope: pdftotext -layout text layer, parsed by extract/extract_target_validation.py

Inspected artifact

Licence
CC-BY-4.0
Source metadata
LLMs for Bayesian Optimization in Scientific Domains: Are We There Yet?

Original source ↗

No field-specific location recorded

Version: Findings of the Association for Computational Linguistics: EMNLP 2025, pages 15482-15510
Retrieved: 2026-10-09T20:55:36Z

catalogued

No individual claim review recorded

Audit details

Field: attributes.licence

Source artifact SHA-256: 7dda0b590f2736b7d30e48b97167a0868a2b4bde253589d8aff7929d01506ff9

Hash scope: pdftotext -layout text layer, parsed by extract/extract_target_validation.py

Inspected artifact

Media type
application/pdf
Source metadata
LLMs for Bayesian Optimization in Scientific Domains: Are We There Yet?

Original source ↗

No field-specific location recorded

Version: Findings of the Association for Computational Linguistics: EMNLP 2025, pages 15482-15510
Retrieved: 2026-10-09T20:55:36Z

catalogued

No individual claim review recorded

Audit details

Field: attributes.media_type

Source artifact SHA-256: 7dda0b590f2736b7d30e48b97167a0868a2b4bde253589d8aff7929d01506ff9

Hash scope: pdftotext -layout text layer, parsed by extract/extract_target_validation.py

Inspected artifact

Publication status
peer_reviewed
Source metadata
LLMs for Bayesian Optimization in Scientific Domains: Are We There Yet?

Original source ↗

No field-specific location recorded

Version: Findings of the Association for Computational Linguistics: EMNLP 2025, pages 15482-15510
Retrieved: 2026-10-09T20:55:36Z

catalogued

No individual claim review recorded

Audit details

Field: attributes.publication_status

Source artifact SHA-256: 7dda0b590f2736b7d30e48b97167a0868a2b4bde253589d8aff7929d01506ff9

Hash scope: pdftotext -layout text layer, parsed by extract/extract_target_validation.py

Inspected artifact

Retrieved at
2026-10-09T20:55:36Z
Source metadata
LLMs for Bayesian Optimization in Scientific Domains: Are We There Yet?

Original source ↗

No field-specific location recorded

Version: Findings of the Association for Computational Linguistics: EMNLP 2025, pages 15482-15510
Retrieved: 2026-10-09T20:55:36Z

catalogued

No individual claim review recorded

Audit details

Field: attributes.retrieved_at

Source artifact SHA-256: 7dda0b590f2736b7d30e48b97167a0868a2b4bde253589d8aff7929d01506ff9

Hash scope: pdftotext -layout text layer, parsed by extract/extract_target_validation.py

Inspected artifact

How to read the evidence

Sources and history

Release 2026-11-02-a7f03c9e55a5 · Record review: source checked

Primary source retrieved and hashed for the therapeutic target validation use-case pass.

Release history

No supporting source is linked yet.

Read original source

Download this release (gzip)
Technical metadata and extraction receipts

Stable ID: tgtval-20261009-source-gupta2025

areas
cells-tissues
contexts
research
url
https://aclanthology.org/2025.findings-emnlp.838/
artifact url
https://aclanthology.org/2025.findings-emnlp.838.pdf
version
Findings of the Association for Computational Linguistics: EMNLP 2025, pages 15482-15510
retrieved at
2026-10-09T20:55:36Z
artifact sha256
7dda0b590f2736b7d30e48b97167a0868a2b4bde253589d8aff7929d01506ff9
publication status
peer_reviewed
licence
CC-BY-4.0
media type
application/pdf
doi
10.48550/arXiv.2509.21403
source locator
Full artifact bytes; per-record locators on each record
access and reuse
CC-BY-4.0 permits redistribution of the article bytes.
archive note
Not archived in the batch although the licence permits it: the PDF is 475,883 bytes and the repository keeps releases small. The artifact_sha256 pins the bytes that were read.
extraction method
pdftotext -layout text layer, parsed by extract/extract_target_validation.py
version note
The DOI recorded is the arXiv preprint (arXiv:2509.21403) of the same work; the bytes read are the ACL Anthology version of record.
Related records

    Suggest a correction